EpiCapture

EpiCapture Limited, a spinout from University College Dublin, specializes in developing non-invasive liquid biopsy tests aimed at early and accurate cancer detection. Founded in 2021 by Dr. Antoinette Perry and Edward Simons, the company focuses on translating scientific research into practical diagnostic solutions. EpiCapture's primary product, EpiCapture Prostate, is a urine-based test designed to detect aggressive prostate cancer, offering a less invasive alternative to traditional methods. The company is also working on developing a similar test for ovarian cancer. Operating in the healthcare diagnostics market, EpiCapture serves patients and clinicians by providing a seamless solution that aids in informed decision-making, potentially reducing the need for costly and risky surgical procedures. The business model revolves around commercializing translational research, with a focus on patient-centric solutions that can be frequently administered with minimal discomfort. EpiCapture generates revenue through the sale of its diagnostic tests, targeting healthcare providers and institutions seeking reliable and repeatable cancer detection methods.

Keywords: liquid biopsy, cancer detection, prostate cancer, ovarian cancer, non-invasive, diagnostics, translational research, patient-centric, healthcare, commercialization.